Visceral hypersensitivity is considered a key mechanism in the pathogenesis of functional gastrointestinal (GI) disorders. Targeting visceral hypersensitivity seems an attractive approach to the development of drugs for functional GI disorders. This review summarizes current knowledge on targets for the treatment of visceral hypersensitivity, and the status of current and future drug and probiotic treatment development, and the role of pharmacogenomic factors.
BUENO L., DE PONTI F., FRIED M., KULLAK-UBLICK G.A., KWIATEK M.A., POHL D., et al. (2007). Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. NEUROGASTROENTEROLOGY AND MOTILITY. SUPPLEMENT, 19 (Suppl. 1), 89-119.
Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity
DE PONTI, FABRIZIO;
2007
Abstract
Visceral hypersensitivity is considered a key mechanism in the pathogenesis of functional gastrointestinal (GI) disorders. Targeting visceral hypersensitivity seems an attractive approach to the development of drugs for functional GI disorders. This review summarizes current knowledge on targets for the treatment of visceral hypersensitivity, and the status of current and future drug and probiotic treatment development, and the role of pharmacogenomic factors.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
